An Open-Label, Nonrandomized Study to Evaluate the Potential Pharmacokinetic Interaction Between Multiple Doses of Verapamil Immediate Release (IR) and a Single Dose of SAM-531 When Co-Administered Orally to Healthy Young Adult Subjects.

Trial Profile

An Open-Label, Nonrandomized Study to Evaluate the Potential Pharmacokinetic Interaction Between Multiple Doses of Verapamil Immediate Release (IR) and a Single Dose of SAM-531 When Co-Administered Orally to Healthy Young Adult Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Feb 2010

At a glance

  • Drugs Cerlapirdine; Verapamil
  • Indications Alzheimer's disease; Angina pectoris; Arrhythmias; Hypertension
  • Focus Pharmacokinetics
  • Sponsors Wyeth
  • Most Recent Events

    • 12 Feb 2010 Actual patient number (14) added as reported by ClinicalTrials.gov.
    • 15 Jul 2009 Additional trial location (France) identified as reported by ClinicalTrials.gov.
    • 15 Jul 2009 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top